Severity of COVID-19 in hospitalized patients with and without atopic disease
© 2021 The Authors..
Background: Data from the 2009 influenza pandemic suggested asthma might protect from severe disease in hospitalized patients. Asthma does not appear to increase risk for hospitalization or mortality with COVID-19.
Objective: This study was undertaken to see if atopy actually protected those hospitalized with COVID-19.
Methods: Retrospective chart review on all patients testing positive for SARS-CoV-2 over 2 months at a major adult and pediatric tertiary referral center hospital. Charts were evaluated for history of atopic disease, as were the need for ICU admission, requirement for supplemental oxygen and/or intubation, and in hospital mortality.
Results: No significant differences in outcomes for patients (n = 275) based on atopic disease were noted: ICU admission, 43% versus 44.7% (atopic versus no atopic disease, respectively; p = 0.84); supplemental oxygen use, 79.1% versus 73.6% (p = 0.36); intubation rate, 35.8% versus 36.5% (p = 0.92); and mortality rate, 13.4% versus 20.7% (p = 0.19). More patients with atopic disease had COPD listed as a diagnosis in their chart (38.8% versus 17.3%, p < 0.001). COPD was associated with an increased rate of ICU admission (aOR = 2.22 (1.15, 4.30) p = 0.02) and intubation (aOR = 2.05 (1.07, 3.92) p = 0.03). After adjusting for COPD, patients with atopic disease had a trend for reduced mortality (aOR 0.55 (0.23, 1.28), p = 0.16), but those with asthma did not (p > 0.2).
Conclusion: Severity of COVID-19 in hospitalized patients does not differ based on atopic status. However, adjusting for presence of COPD led to a suggestion of possible reduced severity in patients with atopy but not asthma.
| Media Type: |
Electronic Article |
|---|
| Year of Publication: |
2021 |
|---|
| Contained In: |
The World Allergy Organization journal - Vol. 14, No. 2 (2021), p. 100508 |
|---|
| Language: |
English |
|---|
| Contributors: |
Timberlake, Dylan T |
|---|
| Urls: |
|---|
| Notes: |
Date Revised 02.02.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine |
|---|
| Physical Description: |
Online-Ressource |
|---|
| doi: |
10.1016/j.waojou.2021.100508 |
|---|---|
| PMID: |
33520082 |
| PPN (Catalogue-ID): |
NLM321855027 |
|---|
| LEADER | 04899nma a2200925 c 4500 | ||
|---|---|---|---|
| 001 | NLM321855027 | ||
| 003 | DE-601 | ||
| 005 | 20210202215135.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210201s2021 000 0 eng d | ||
| 024 | 7 | |a 10.1016/j.waojou.2021.100508 |2 doi | |
| 028 | 5 | 2 | |a pubmed21n1132.xml |
| 035 | |a (DE-599)NLM33520082 | ||
| 040 | |b ger |c GBVCP | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Timberlake, Dylan T | |
| 245 | 1 | 0 | |a Severity of COVID-19 in hospitalized patients with and without atopic disease |h Elektronische Ressource |
| 300 | |a Online-Ressource | ||
| 500 | |a Date Revised 02.02.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 500 | |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine | ||
| 520 | |a © 2021 The Authors. | ||
| 520 | |a Background: Data from the 2009 influenza pandemic suggested asthma might protect from severe disease in hospitalized patients. Asthma does not appear to increase risk for hospitalization or mortality with COVID-19 | ||
| 520 | |a Objective: This study was undertaken to see if atopy actually protected those hospitalized with COVID-19 | ||
| 520 | |a Methods: Retrospective chart review on all patients testing positive for SARS-CoV-2 over 2 months at a major adult and pediatric tertiary referral center hospital. Charts were evaluated for history of atopic disease, as were the need for ICU admission, requirement for supplemental oxygen and/or intubation, and in hospital mortality | ||
| 520 | |a Results: No significant differences in outcomes for patients (n = 275) based on atopic disease were noted: ICU admission, 43% versus 44.7% (atopic versus no atopic disease, respectively; p = 0.84); supplemental oxygen use, 79.1% versus 73.6% (p = 0.36); intubation rate, 35.8% versus 36.5% (p = 0.92); and mortality rate, 13.4% versus 20.7% (p = 0.19). More patients with atopic disease had COPD listed as a diagnosis in their chart (38.8% versus 17.3%, p < 0.001). COPD was associated with an increased rate of ICU admission (aOR = 2.22 (1.15, 4.30) p = 0.02) and intubation (aOR = 2.05 (1.07, 3.92) p = 0.03). After adjusting for COPD, patients with atopic disease had a trend for reduced mortality (aOR 0.55 (0.23, 1.28), p = 0.16), but those with asthma did not (p > 0.2) | ||
| 520 | |a Conclusion: Severity of COVID-19 in hospitalized patients does not differ based on atopic status. However, adjusting for presence of COPD led to a suggestion of possible reduced severity in patients with atopy but not asthma | ||
| 611 | 2 | 7 | |a Journal Article |2 gnd |
| 655 | 7 | |a Asthma |2 gnd | |
| 655 | 7 | |a Atopy |2 gnd | |
| 655 | 7 | |a CDC, Centers for Disease Control and Prevention |2 gnd | |
| 655 | 7 | |a COPD, Chronic Obstructive Pulmonary Disease |2 gnd | |
| 655 | 7 | |a COVID-19 |2 gnd | |
| 655 | 7 | |a COVID-19, Coronavirus Disease 2019 |2 gnd | |
| 655 | 7 | |a CRP, C Reactive Peptide |2 gnd | |
| 655 | 7 | |a Hospitalization |2 gnd | |
| 655 | 7 | |a ICS, Inhaled corticosteroid |2 gnd | |
| 655 | 7 | |a ICU, Intensive Care Unit |2 gnd | |
| 655 | 7 | |a Il-6, Interleukin 6 |2 gnd | |
| 655 | 7 | |a LABA, Long acting beta agonist |2 gnd | |
| 655 | 7 | |a NHANES, National Health and Nutrition Examination Survey |2 gnd | |
| 655 | 7 | |a RAST, Radioallergosorbent test |2 gnd | |
| 655 | 7 | |a RT-PCR, Real time polymerase chain reaction |2 gnd | |
| 655 | 7 | |a SARS-CoV-2 |2 gnd | |
| 655 | 7 | |a SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 |2 gnd | |
| 655 | 7 | |a Severity |2 gnd | |
| 689 | 0 | 0 | |A f |a Journal Article |
| 689 | 0 | |5 DE-601 | |
| 689 | 1 | 0 | |a Asthma |
| 689 | 1 | 1 | |a Atopy |
| 689 | 1 | 2 | |a CDC, Centers for Disease Control and Prevention |
| 689 | 1 | 3 | |a COPD, Chronic Obstructive Pulmonary Disease |
| 689 | 1 | 4 | |a COVID-19 |
| 689 | 1 | 5 | |a COVID-19, Coronavirus Disease 2019 |
| 689 | 1 | 6 | |a CRP, C Reactive Peptide |
| 689 | 1 | 7 | |a Hospitalization |
| 689 | 1 | 8 | |a ICS, Inhaled corticosteroid |
| 689 | 1 | 9 | |a ICU, Intensive Care Unit |
| 689 | 1 | X | |a Il-6, Interleukin 6 |
| 689 | 1 | X | |a LABA, Long acting beta agonist |
| 689 | 1 | X | |a NHANES, National Health and Nutrition Examination Survey |
| 689 | 1 | X | |a RAST, Radioallergosorbent test |
| 689 | 1 | X | |a RT-PCR, Real time polymerase chain reaction |
| 689 | 1 | X | |a SARS-CoV-2 |
| 689 | 1 | X | |a SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 |
| 689 | 1 | X | |a Severity |
| 689 | 1 | |5 DE-601 | |
| 700 | 1 | |a Narayanan, Deepika | |
| 700 | 1 | |a Ogbogu, Princess U | |
| 700 | 1 | |a Raveendran, Rekha | |
| 700 | 1 | |a Porter, Kyle | |
| 700 | 1 | |a Scherzer, Rebecca | |
| 700 | 1 | |a Prince, Benjamin | |
| 700 | 1 | |a Grayson, Mitchell H | |
| 773 | 0 | 8 | |i in |t The World Allergy Organization journal |g Vol. 14, No. 2 (2021), p. 100508 |q 14:2<100508 |w (DE-601)NLM194386198 |x 1939-4551 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.waojou.2021.100508 |3 Volltext |
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |e 2 |b 26 |c 02 |h 100508 | ||